TST003
TST003 is a monoclonal antibody from Transcenta Therapeutics (Hangzhou) Co., Ltd., in registered phase 2 trials for colorectal cancer.
Overview
TST003 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Transcenta Therapeutics (Hangzhou) Co., Ltd., in colorectal cancer. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A monoclonal antibody, as described in the registry record.
1.TST003 binds its target.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"TST003" OR ABSTRACT:"TST003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TST003, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentOnvansertib
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentSotevtamab
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentCT3001
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentEIK1005
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentJMT203
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentVB15010
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentBalstilimab
Shares Colorectal cancer and the tags pipeline, registry-only.
- TreatmentAdavosertib
Shares the tags pipeline, registry-only.